Tag - FATE

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...